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Snow Mountain virus (GII.2.1976) is the prototype strain of GII.2 noroviruses (NoVs), which cause an estimated 8% of norovi-
rus outbreaks, yet little is known about the immunobiology of these viruses. To define the human immune response induced by
SMV infection and the antigenic relationship between different GII.2 strains that have circulated between 1976 and 2010, we de-
veloped a panel of four GII.2 variant virus-like particles (VLPs) and compared their antigenicities by enzyme immunoassay
(EIA) and surrogate antibody neutralization (blockade) assays. Volunteers infected with GII.2.1976 developed a mean 167-fold
increase in blockade response against the homotypic VLP by day 8 postchallenge. Blockade extended cross-genotype activity in
some individuals but not cross-genogroup activity. Polyclonal sera from GII.2.1976-infected volunteers blocked GII.2.1976 sig-
nificantly better than they blocked GII.2.2002, GII.2.2008, and GII.2.2010, suggesting that blockade epitopes within the GII.2
strains have evolved in the past decade. To potentially map these epitope changes, we developed mouse monoclonal antibodies
(MAbs) against GII.2.1976 VLPs and compared their reactivities to a panel of norovirus VLPs. One MAb had broad cross-geno-
group EIA reactivity to a nonblockade, linear, conserved epitope. Six MAbs recognized conformational epitopes exclusive to the
GII.2 strains. Two MAbs recognized GII.2 blockade epitopes, and both blocked the entire panel of GII.2 variants. These data in-
dicate that the GII.2 strains, unlike the predominant GII.4 strains, have undergone only a limited amount of evolution in block-
ade epitopes between 1976 and 2010 and indicate that the GII.2-protective component of a multivalent norovirus vaccine may
not require frequent reformulation.
Noroviruses (NoVs) are the leading cause of viral acute gastro-enteritis globally, resulting in over 20 million cases annually
in the United States alone. Worldwide, an estimated 200,000
deaths occur each year in developing countries among children
under age 5 (1, 2). Young children, the elderly, and the immuno-
compromised are the most susceptible populations to complica-
tions arising from norovirus infection (3–5). With an infectious
dose of as few as 20 viral particles, large quantities of viral shed-
ding, and resistance to many chemical disinfectants, noroviruses
have been referred to as “the perfect human pathogen” (6). The
onset of symptoms occurs 10 to 24 h following exposure, and the
duration of severe gastroenteritis resolves after 24 to 48 h in most
cases (7), but there are instances of chronic infection, primarily in
immunocompromised individuals (8–10). Prevention of trans-
mission is complicated by the fact that not all infected individuals
are symptomatic, and viral shedding can occur for weeks after
symptoms have resolved (1).
Members of the family Caliciviridae, noroviruses are 7.5-kb
positive-sense, single-stranded RNA viruses that are structurally
composed of three open reading frames (ORFs). ORF1 encodes
the nonstructural proteins, including the RNA-dependent RNA
polymerase (RdRp). ORF2 and ORF3 encode the major (VP1)
and minor (VP2) structural proteins, respectively (11, 12). The
sequence of ORF2 is used to classify noroviruses; sequence iden-
tity of 85% corresponds to the strain, 56.2 to 85% to the geno-
type, and 38.6 to 55% to the genogroup (12). Genogroup I (GI)
and GII strains cause almost all human NoV infections. Within GI
and GII, there are currently 31 different genotypes (13), although
enhanced outbreak investigation continues to expand the number
of identified NoV genotypes.
Structurally, the major capsid protein is composed of the shell
(S) domain, and the protruding (P) domain, which is further di-
vided into the P1 and P2 subdomains. Ninety copies of dimerized
S domain make up the icosahedral shell. The P1 subdomain forms
a stalk rising from the shell, while the P2 subdomain forms the tip
of the protrusion of the capsomere and is responsible for histo-
blood group antigen (HBGA) binding and a majority of identified
antibody recognition sites (14–17). The P2 subdomain of GII.4
NoVs is under selective pressure and subsequently is hypervari-
able. Changes in the P2 subdomain result in loss of VLP reactivity
with potentially neutralizing “blockade” antibodies and correlate
with the emergence of new, antigenically distinct, GII.4 strains.
Additionally, P2 amino acid changes have been shown to influ-
ence HBGA binding of GII.4 strains, potentially modulating pop-
ulation susceptibility. While immune escape and variable HBGA
binding are well documented for GII.4 NoV strains, the impact of
viral evolution on other NoV genotypes is not well characterized.
GII.4 strains, which cause a majority (70 to 80%) of NoV out-
breaks, have undergone an 9% amino acid substitution rate in
the capsid protein sequence over 12 years (18–23). In comparison,
GII.2 strains cause about 8% of NoV infections and have only
2.6% amino acid diversity in the GII.2 capsid over a similar time
frame (4). Harris et al. (4) have proposed that the evolution in the
capsid gene of the GII.2 variants is due to selective pressure caus-
ing genetic drift, similar to the emergence of new GII.4 variants
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(20, 21, 25, 26). Importantly, this suggestion was based solely on
predictive biology. To date, there have been no empirical data
demonstrating that the natural variation in the capsid gene of
GII.2 strains results in viruses of altered antigenicity or receptor
binding properties.
Due to a lack of a cell culture or small animal model for human
noroviruses, in vitro assays have been used to characterize evolu-
tion and immunity. Samples collected during human challenge
studies and outbreak investigations allow characterization of im-
mune responses using in vitro assays. Various studies have found
that HBGAs, found in mucosal secretions as well as on the surface
of epithelial cells, are norovirus cell attachment factors (27–30).
The capacity of human polyclonal sera to inhibit NoV VLP bind-
ing to HBGAs has been shown to correlate with protection from
infection (31, 32). While enzyme immunoassays (EIAs) measure
the presence or absence of reactive antibody, neutralization assays
measure the potential protective activity of an antibody (20, 33,
34). Our group has pioneered the development of NoV surrogate
neutralization assays (22, 35, 36), based on antibody “blockade” of
VLP-carbohydrate ligand interactions.
What little is known about GII.2 susceptibility and immunity
comes from studying naturally and experimentally infected hu-
mans. Utilizing a human challenge model, we challenged 15 vol-
unteers with 10, 103, or 105 reverse transcription-PCR-detectable
units of GII.2.1976 Snow Mountain virus (SMV) and evaluated
potential susceptibility markers and immune responses in the
subjects (37). Contrary to GI.1.1968 NoV, GII.2.1976 infection
was not dependent on secretor or Lewis phenotypes in this small
trial. In vitro, GII.2.1976 VLPs bound exclusively to type B saliva
and not to synthetic biotinylated di- or trivalent saccharides (33,
38). However, subjects with O, A, and secretor-negative pheno-
types became infected in this study, identifying the same disparity
in GII.2.1976 virus infection and in vitro VLP-ligand binding that
was evident in a much-larger-scale human challenge study with
GI.1.1968 NoV. Although GI.1.1968 did not bind to type B saliva
or biotinylated synthetic carbohydrate, 43% (28) and 75% (27) of
B-positive subjects became infected when challenged with live
GI.1.1968 virus. These studies suggest that in vitro binding profiles
of norovirus VLPs correlate with the relative risk of norovirus
infection but do not define absolute susceptibility profiles, espe-
cially at high virus doses (27). This discrepancy may be due to
subtle differences between carbohydrate expression in saliva and
that in the gut. Furthermore, GII.2.1976 infection induced a sig-
nificant increase in homotypic serum IgG by day 8 postchallenge,
as measured by EIA (37). The SMV-induced IgG cross-reacted
with another GII VLP, but not with a GI VLP. Similar cross-reac-
tivity results were characterized for CD4 T cell responses. To
date, nothing is known about the neutralization potential of IgG
induced by GII.2 infection.
In this follow up study, we developed a surrogate neutraliza-
tion assay for GII.2 NoVs based on VLP binding to B saliva. We
used this assay to evaluate the timing of blockade antibody devel-
opment after GII.2.1976 challenge and then compared the cross-
reactive blockade of both human challenge sera and monoclonal
antibodies (MAbs) to a panel of time-ordered GII.2 VLPs to assess
the extent of antigenic evolution in this NoV genotype. Both hu-
man challenge sera and MAbs suggest that the GII.2 lineage of
NoV is under limited pressure from herd immunity and has re-
mained relatively antigenically static over the past 35 years. These
results may explain why GII.2 NoVs cause only limited numbers
of outbreaks and provide support for a single GII.2 component in
an NoV multivalent vaccine.
MATERIALS AND METHODS
VLPs. GII.2 ORF2 genes (GII.2.1976 SMV [GenBank accession no.
AY134748.1], GII.2.2002 Ina, [accession no. AB195225.1], GII.2.2008
Osaka City [accession no. AB662868.1], and GII.2.2010 Osaka City [ac-
cession no. AB662899.1]) were inserted into the VEE pVR21 replicon
vector to create virus replicon particles (VRPs) and virus-like particles
(VLPs) assembled in VRP-infected BHK-21 cells, as formerly described by
our group (20, 39–41). Briefly, VLPs were purified by velocity sedimen-
tation, the sucrose was diluted out with phosphate-buffered saline (PBS),
and the VLPs were concentrated in an Amicon Ultra 100-kDa molecular
mass cutoff centrifugal unit (Millipore, Billerica, MA). The purity of VLP
preparations was determined by Coomassie blue-stained SDS-PAGE gels.
Negative staining with uranyl acetate, followed by imaging on a LEO
EM-910 transmission electron microscope, was done to evaluate the
structural integrity of the particles. A bicinchoninic acid (BCA) protein
assay (Thermo-Fisher) was performed to determine the protein concen-
tration.
Study design and subjects. Archival serum samples from our previous
SMV human challenge study conducted in 2001 were used in this study
(37). Of the 15 original challenge study volunteers, serum samples from 13
subjects were available for analysis of blockade titer. All study protocols
and methods were approved by the University of North Carolina School
of Medicine Committee for Protection of Human Subjects. All volunteers
participated after providing informed consent.
EIAs. Antibody binding was detected by enzyme immunoassays
(EIAs), performed as previously described (22). Briefly, EIA high-bind-
ing, easy-wash plates were coated with 0.5 g/ml VLP in phosphate-buff-
ered saline (PBS) before addition of 2-fold serial dilutions of mouse
monoclonal antibody (MAb) or polyclonal serum. The primary antibody
incubation was followed by 1:10,000 horseradish peroxidase (HRP)-con-
jugated secondary antibody (GE Healthcare) and development with
3,3=,5,5=-tetramethylbenzidine (TMB) Ultra (Thermo Scientific). Plates
were washed with PBS– 0.05% Tween 20 between each step, and all anti-
body dilutions were performed in 5% Blotto in PBS– 0.05% Tween 20.
Plates were read at the optical density at 450 nm (OD450), and 50% effec-
tive concentration (EC50) values were calculated using a sigmoidal dose-
response curve and GraphPad Prism version 6.02 for Windows, Graph-
Pad Software, La Jolla, CA. All data points represent an average of at least
three replicates from a minimum of 2 independent runs. Antibodies were
considered positive for reactivity if the mean optical density of the maxi-
mum binding, after subtraction of the background, was at least 0.2 (42). If
the mean optical density was less than 0.2, the antibody was determined to
be nonreactive and assigned a value of 2-fold the limit of detection, and
the EC50 was represented on graphs by a data marker above the limit of
detection (dashed lines).
Carbohydrate-binding and blockade assay. EIA high-binding, easy-
wash plates were coated with 50 l per well of processed saliva (28, 37)
diluted 1/500 in PBS and blocked with 5% Blotto in PBS– 0.05% Tween 20
before the addition of serial dilutions of VLP. VLP binding was detected
with 1/500 rabbit anti-GII.2.1976 polyclonal sera, followed by 1:10,000
HRP-conjugated goat anti-rabbit secondary antibody (GE Healthcare).
All antibody incubations were performed at room temperature in 5%
Blotto in PBS– 0.05% Tween 20. Plates were washed with PBS-Tween 20
three times, with 15- to 60-s soaks between each step. TMB Ultra was
added to each well, the mixture was incubated for 10 min, color develop-
ment was stopped by adding 50 l 2 M sulfuric acid, plates were read at
OD450, and half-maximal binding was calculated.
For blockade assays, 0.5 g/ml VLP, either alone or pretreated with
serial dilutions of serum or MAb for 30 min, was added to saliva-coated
plates, and the mixture was incubated at room temperature for 90 min.
The percentage of control binding was defined as the amount of VLP
bound to the carbohydrate-coated plate in the presence of antibody pre-
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treatment divided by the amount of VLP bound in the absence of antibody
pretreatment multiplied by 100. EC50 values were calculated by using the
reciprocal of the dilution of serum or g/ml of purified antibody. All
experiments were performed at least three times in duplicate. The criteria
used to determine if an antibody was a blockade antibody were (i) block-
ade of at least 50% of the VLP-carbohydrate interaction within the dilu-
tion series tested and (ii) a positive dose response between antibody con-
centration and mean percentage of control binding, as determined by a
Hill slope absolute value greater than 0.8.
Production of mouse monoclonal antibodies. Swiss Webster mice
were immunized intraperitoneally (i.p.) on days 0, 20, and 40 with 50 g
of VLP in PBS plus 50 l Gerbu adjuvant (Thermo Fisher). On day 80,
mice were boosted before splenocytes were chemically fused with mouse
myeloma line P3X63-AG8.653 on day 84. Aminopterin was added to the
media to select for fused cells, the resulting hybridomas were screened by
EIA, and clonal colonies were isolated by limiting dilution subcloning.
The resulting antibodies were isotyped (Roche) and purified by protein G
chromatography (GE Healthcare).
Western blots. VLPs were suspended in Laemmli loading buffer and
loaded at 9 g of protein in a prep-well 7.5% SDS-polyacrylamide gel
(Bio-Rad). Electrophoresed proteins were transferred to a polyvinylidene
difluoride (PVDF) membrane (Bio-Rad) and blocked. Immobilized pro-
teins were probed with 1 or 5 g/ml MAb at 37°C, which was detected
with HRP-conjugated goat anti-mouse IgG secondary antibody (GE
Healthcare). The ECL enhanced chemiluminescence Western blotting de-
tection kit (GE Healthcare) was used to visualize antibody-reactive pro-
tein. Each step was followed by multiple washings with PBS– 0.05%
Tween 20, and reagents were diluted in 5% Blotto in PBS– 0.05%
Tween 20.
Structural models of GII.2 P domains. The amino acid sequences of
GII.2.1976, GII.2.2002, GII.2.2008, and GII.2.2010 capsids were individ-
ually aligned to the VA387 P domain sequence using Clustalx1.86, and the
GII.4.2002 P domain dimer X-ray crystal structure (PDB accession no.
2OBT) was used as a template for generation of homology models. Ho-
mology models were generated using the program Modeler available via
the Max Planck Institute Bioinformatics Toolkit (http://toolkit.tuebingen
.mpg.de/). The structural models were analyzed and compared, and fig-
ures were generated using Mac Pymol (Delano Scientific).
Statistical analysis. One-way analysis of variance (ANOVA) followed
by Dunnett’s multiple comparisons test was performed when three or
more values were compared; direct comparisons between two values were
measured using the unpaired t test. For statistical significance, P  0.05
was considered significant. All statistics were done using GraphPad Prism
Software.
RESULTS
SMV infection induces a strong intragenotype blockade re-
sponse. The sequence of the P2 domain of GII.2 strains has
evolved over time, although less extensively than has been re-
ported for GII.4 NoV strains (24). To determine if these GII.2
residue changes led to antigenic differences between the GII.2
NoV strains, we performed a multiple sequence alignment with 10
GII.2 capsid sequences from GenBank and identified 16 amino
acid substitutions that occurred over time (Fig. 1A). We selected
four sequences that represented the diversity of sequence identity,
and when the amino acid differences between the four GII.2 ref-
erence sequences were mapped onto a GII.4.2002 P dimer model,
the model showed that the differences mapped to the most-sur-
face-exposed ridges of the GII.2 capsid (Fig. 1B). To determine if
these surface changes resulted in antigenicity changes, we synthe-
sized four time-ordered GII.2 VLPs representing strains that cir-
culated between 1976 and 2010 for comparison. Structural integ-
rity of the new GII.2 VLPs was verified by transmission electron
microscopy (TEM) visualization of 40-nm particles and confir-
mation of carbohydrate binding to saliva (Fig. 1C and D).
GII.2.1976 and GII.2.2002 VLPs bound preferentially to type B
saliva, requiring significantly more VLP to reach half-maximum
binding to type A saliva (33, 38). In comparison, the more con-
temporary GII.2 strain VLPs,GII.2.2008 and GII.2.2010, bound to
type B and A saliva similarly (Fig. 1D), suggesting that residue
changes in the P2 domain of GII.2.2008 and 2010 may have influ-
enced VLP affinity for an expanded set of histo-blood group anti-
gens, as has been reported for GII.4 NoVs.
Using B saliva as the carbohydrate binding ligand for GII.2 (43,
44), we evaluated archived serum samples from our original SMV
human challenge study for the capacity to block homotypic VLP-
ligand interactions. We observed two homotypic blockade re-
sponse phenotypes. As a group, infected subjects did not have any
detectable blockade activity at day 0 (EC50 titer below the limit of
detection) but progressed to a significantly increased blockade
response by day 8 postchallenge EC50 of 4,178 (95% confidence
interval [CI], 3,327 to 5,247) (Fig. 2A), representing an estimated
167-fold increase in blockade titer. Titers remained high through
day 21, the final day of sample collection. As a group, uninfected
subjects had low but detectable SMV blockade titers at day 0, and
these titers did not vary significantly over the course of sample
collection (Fig. 2B). At day 0, the GII.2.1976 blockade titer was
116.3 (95% CI, 101.0 to 133.8), with 5 of the 6 uninfected individ-
uals having detectable preexisting blockade titers. At day 8 post-
challenge, mean titers remained consistent at 151.7 (95% CI,
124.7 to 184.6). The results from these blockade assays parallel the
homotypic, human polyclonal IgG serum responses measured by
EIA, in which infected individuals had a significant increase in
SMV-specific antibodies postinfection (37), and provide the first
evidence that SMV infection induces an antibody response target-
ing potentially neutralizing epitopes.
Changes in the sequence of the capsid gene of GII.4 norovi-
ruses have been suggested as a mechanism to escape herd im-
munity, resulting in the emergence of new antigenically dis-
tinct pandemic strains every few years (18–20, 22, 25, 34). To
test if the GII.2 strains are undergoing a similar antigenic drift,
we determined the capacity of polyclonal sera from SMV-chal-
lenged subjects to block other GII.2 VLPs (Fig. 3). As a group,
the infected subjects had no detectable blockade titer at day 0
and developed increased blockade titers to the entire panel of
GII.2 VLPs by day 8, although significantly more serum was
needed to block GII.2.2002, -2008, and -2010 than GII.2.1976.
Blockade of GII.2.2002 required 1.5-fold more sera (EC50,
2,765; 95% CI, 2,287 to 3,342), GII.2.2008 required 2.5-fold
more serum (EC50, 1,552; 95% CI, 983.5 to 2,451), and
GII.2.2010 required 5-fold more serum (EC50, 843.8; 95% CI,
693.7 to 1,026) to block 50% of VLP-ligand interaction (Fig.
3A). As a group, sera from the uninfected subjects had low
blockade titers at day 0 (200 for each VLP), and these titers
remained consistent at day 8 (200 for each VLP) (Fig. 3B). Of
note, even in the uninfected subjects, significantly more serum
was needed to block binding of GII.2.2010 (EC50, 56.68; 95%
CI, 53.54 to 60.01) than was needed to block GII.2.1976 (EC50,
152; 95% CI, 125 to 185). While increasing amounts of SMV-
induced polyclonal sera were required to block GII.2 VLP
binding to saliva in a time-dependent pattern in infected sub-
jects, none of the GII.2 variants tested changed antigenicity
enough to completely escape antibody blockade, suggesting
that GII.2 strains have undergone a limited degree of evolution
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in antibody blockade epitopes during the 34-year period exam-
ined.
SMV infection induces a modest cross-genotype blockade re-
sponse in some subjects. To determine if antibodies produced in
response to Snow Mountain virus infection not only recognize
blockade epitopes conserved within the genotype but also
recognize those within the genogroup, serum samples were exam-
ined for ligand interaction blockade of GII.3.1999 (Toronto),
GII.4.1997 (the circulating GII.4 strain at the time of the SMV
challenge study), and GI.1.1968 (Norwalk) VLPs. As a group, day
0 sera from infected volunteers did not have any blockade activity
for any of the VLPs tested. At day 8, cross-genotype blockade titers
had risen 3-fold for GII.3.1999 (EC50, 81.98; 95% CI, 58.94 to
114.0). Day 8 sera did not block GII.4.1997 or GI.1.1968 (Fig. 4A).
As a group, the sera from uninfected subjects did not have any
blockade titer, and that titer remained below levels of detection at
day 8 (Fig. 4B). Individually, two of the infected subjects had at
least a 4-fold increase in blockade antibodies against GII.3.1999.
This cross-reactive blockade potential extended to GII.4.1997 in
one of these subjects, and another subject had at least a 4-fold
increase in blockade antibodies against only GII.4.1997. None of
the individual uninfected subjects had at least a 4-fold change in
blockade titer to any of the cross-genotype VLPs tested (data not
shown).
Anti-GII.2.1976 SMV MAb characterization. The variances in
blockade between GII.2 VLPs by polyclonal sera (Fig. 3) indicate
the possibility that some blockade epitopes may by changing over
time. To potentially map the GII.2 antigenic variation, we devel-
oped a panel of seven mouse MAbs against the GII.2.1976 VLP
(18, 21, 41). The MAbs were purified, isotyped, and screened by
Western blotting for reactivity to linear epitopes in the major cap-
sid protein of GII.2.1976 (Table 1) and against a panel of GI and
GII VLPs by EIA for reactivity to conformational epitopes (Fig. 5
and 6). All seven MAbs recognize the panel of GII.2 VLPs by EIA
(Fig. 5). SMV37, SMV59, SMV114, and SMV129 bound more
contemporary GII.2 strain VLPs at significantly lower EC50 titers
than they bound to the homotypic GII.2.1976 VLP. One MAb,
SMV130, bound all four GII.2 VLPs similarly, and 2 MAbs,
SMV187 and SMV276, required more antibody to reach 50%
maximum binding to GII.2.2002 than was needed to bind the
other GII.2 strain VLPs. Uniquely, SMV59 reacted outside the
GII.2 genocluster and bound to a diverse panel of NoV VLPs rep-
resenting GI and GII strains (Fig. 6). The broadly reactive MAb
SMV59 detected the major capsid protein by Western blotting,
indicating that it binds to a linear epitope. The absence of SMV59
reactivity to GII.4.2002, GII.4.2006, and GII.4.2009 P particles by
EIA and Western blotting indicates that the antibody likely targets
a conserved region of the shell domain (data not shown). The
FIG 1 Characterization of GII.2 VLPS. (A) Variations in the P2 domain amino acids within the GII.2 strains are color coded to indicate in what strain the residue
changes originated: GII.2.1976, blue; GII.2.2002, green; GII.2.2008, purple; GII.2.2010, pink. (B) The variation shown in panel A was mapped onto the P domain
dimer, which is shown in two shades of blue representing the two P domain chains of the dimer. (C) Electron microscopy visualization of negative-stained VLPs:
GII.2.1976 SMV, GII.2.2002 Ina, GII.2.2008, and GII.2.2010. (D) GII.2 VLPs were assayed for binding to type A or B saliva by EIA, and the half-maximal binding
was calculated in g/ml. The horizontal dashed line indicates the upper limit of detection. *, binding to type B saliva statistically different from binding to type
A saliva.
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remaining six genotype-specific antibodies recognize conforma-
tional epitopes, as they did not detect the major capsid protein by
Western blot analysis (Table 1).
Each MAb was then evaluated for capacity to inhibit VLP-
carbohydrate interactions, using our surrogate neutralization as-
say. The EIA EC50 titer did not correlate to the blockade titer. Of
the seven MAbs developed against the GII.2.1976 VLP, only
SMV129 and SMV187 blocked the homotypic VLP-ligand interac-
tion, suggesting that these two MAbs recognize blockade epitopes
(Fig. 7). We then examined the cross-reactive blockade capacity of the
MAbs across the panel of GII.2 VLPS. None of the MAbs gained
blockade activity against the heterotypic VLPs. Compared to homo-
typic GII.2.1976-ligand interaction blockade, significantly less
SMV129 was needed to block GII.2.2002, significantly more MAb
was needed to block GII.2.2008, and a similar amount of MAb was
needed to block GII.2.2010. SMV187 blocked the ligand interaction
of the GII.2.1976, -2002, and -2010 strains similarly but required sig-
nificantly more antibody to block GII.2.2008. These data support
findings with polyclonal sera indicating that GII.2.strains have under-
gone limited antigenic changes.
DISCUSSION
Human NoVs are the primary cause of severe acute gastroenteritis
worldwide and in all age groups. Despite this significant disease
burden, susceptibility to and immune protection from NoV infec-
tion are not well understood. The primary complicating factors in
studying NoVs are the lack of a cell culture system for human NoV
propagation and the high degree of genetic heterogeneity within
the NoV family. This genetic heterogeneity translates to both dif-
ferential cellular ligand binding properties and antigenic differ-
ences between the genogroups, genotypes, and even strains within
the same genotype (18, 22, 26, 38, 44–46). These effects are most
pronounced in the GII.4 genotype, where new strain emergence
every 2 to 3 years correlates with loss of reactivity to antibodies
that recognize blockade epitopes and altered affinity for different
HBGAs (18, 19, 21, 34, 45). In contrast, in the GI.1 genotype
antigenicity and HBGA binding have been relatively static over the
past 40 years (28, 35). Little is known about the antigenicity of or
susceptibility to strains within other genotypes or how previous
exposure to different genotypes affects the immune response to a
current virus challenge.
Using a human challenge model with the GII.2.1976 SMV in-
FIG 2 SMV infection induces a strong homotypic blockade response by day 8
postchallenge. Sera collected at days 0 to 5, day 8, day 14, and day 21 post-
GII.2.1976 SMV challenge were assayed for the ability to block the GII.2.1976
SMV interaction with ligand in surrogate neutralization assays. Sigmoidal
dose-response curves were fit to the mean percent control binding (percentage
of VLP bound to ligand in the presence of antibody pretreatment compared to
the amount of VLP bound in the absence of antibody pretreatment), and the
mean EC50 titers for sera from infected (A) and uninfected (B) volunteers were
calculated. Error bars represent 95% confidence intervals. Nonblockade sera
were assigned an EC50 of 25 for statistical analysis and are denoted by data
markers on the graph below the lower limit of detection (dashed line) for visual
comparison. *, sample days with titers at least 4-fold above and significantly
different from day 0 titers.
FIG 3 Serum blockade response modestly differentiates between GII.2 VLPs.
Day 0 and day 8 sera were assayed for ability to block the time-ordered GII.2
VLP interaction with ligand in surrogate neutralization assays. Sigmoidal
dose-response curves were fit to the mean percent control binding (percentage
of VLP bound to ligand in the presence of antibody pretreatment compared to
the amount of VLP bound in the absence of antibody pretreatment), and the
mean EC50 titers for blockade of GII.2.1976 SMV, GII.2.2002, GII.2.2008, and
GII.2.2010 were calculated for infected (A) and uninfected (B) volunteers.
Error bars represent 95% confidence intervals. Nonblockade sera are denoted
by data markers on the graph below the lower limit of detection (dashed line)
for visual comparison. *, day 8 titer significantly different from the GII.2.1976
SMV day 8 titer.
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oculum, we have tested the association between in vitro VLP-
HBGA binding and virus susceptibility. In our earlier studies,
SMV VLPs bound exclusively to type B saliva in single-dilution
binding assays, but subjects of the O, A, and secretor-negative
phenotypes became infected, identifying a discordance between
these two observations that was also seen in similar studies with
GI.1.1968 (28, 37). Here, using a dynamic range of VLP concen-
trations to test saliva binding, GII.2.1976 VLPs were found to bind
preferentially to type B saliva but also to type A saliva, although at
a lower affinity, agreeing with previously published reports (38).
GII.2 VLPs did not bind to any tested type O or secretor-negative
saliva samples in these assays. Even with the expanded HBGA
binding repertoire identified here, the discordance between
GII.2.1976 VLP binding to HBGA-phenotyped saliva and GII.
2.1976 infectivity remains. The preferential binding of type B sa-
liva over type A saliva is retained in GII.2.2002 VLPs, but both
GII.2.2008 and 2010 VLPs bind type A and B saliva similarly.
Although speculative, these data suggest that the more contempo-
rary GII.2 strains may have altered affinities for HBGAs and thus
target susceptible populations different from those targeted by
the earlier GII.2 strains. Of note, residue 354 changed from glycine
in GII.2.1976 and GII.2.2002 to alanine in GII.2.2008 and
GII.2.2010. As previously shown (47), residue 354 of GII.2 strains
is located within the HBGA binding pocket, suggesting that this
change may account for the increased affinity of contemporary
GII.2 strains for type A saliva. Only human challenge studies can
determine if this change has any biological impact on the suscep-
tible population, but cocrystal structures of different GII.2 parti-
cles bound to carbohydrates would provide insight into the effect
of the G354A change on carbohydrate interaction and expand our
understanding of the complex relationship between in vitro
HBGA binding and infection.
This study is the first to measure potentially neutralizing
FIG 4 GII.2.1976 SMV infection induces a modest cross-genotype blockade
response. Day 0 and day 8 sera were assayed for ability to block norovirus VLPs
from additional genotypes in surrogate neutralization assays. Sigmoidal dose-
response curves were fit to the mean percent control binding (percentage of
VLP bound to ligand in the presence of antibody pretreatment compared to
the amount of VLP bound in the absence of antibody pretreatment) and the
mean EC50 titer for blockade of GII.2.1976 SMV, GII.3.1999, GII.4.1997, and
GI.1.1968 Norwalk calculated for infected (A) and uninfected (B) volunteers.
Error bars represent 95% confidence intervals. Nonblockade sera are denoted
by data markers on the graph below the lower limit of detection (dashed line)
for visual comparison. *, day 8 titers at least 4-fold greater than and signifi-
cantly different from day 0 titers.
TABLE 1 Characterization of anti-GII.2.1976 SMV VLP mouse MAbs








a As determined by Western blotting.
FIG 5 The epitopes recognized by anti-GII.2.1976 SMV mouse MAbs are
conserved across the time-ordered panel of GII.2 VLPs. Antibody epitopes
shared among GII.2 VLPs were measured by MAb binding to the time-ordered
VLP panel by EIA, and the half-maximal binding was calculated in g/ml. *,
VLP with a significantly different EC50 from that of GII.2.1976. The horizontal
dashed line indicates the upper limit of detection.
FIG 6 Anti-GII.2.1976 SMV mouse MAb SMV59 binds to an NoV conserved
epitope by EIA. Half-maximal binding in g/ml of SMV59 to a panel of NoV
VLPs was determined by EIA. Error bars represent 95% confidence intervals. *,
VLPs with a significantly different EC50 titer from that of GII.2.1976. The
horizontal dashed line indicates the upper limit of detection.
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“blockade” antibody responses to GII.2 NoVs. As has been shown
for GI.1 and GII.4 NoVs, GII.2.1976 SMV infection correlates
with an increased blockade titer in all tested subjects by day 8
postchallenge, and titers remained elevated at day 21, the final
sample collection day. Although all of the infected subjects had
day 8 titers above 200 (the blockade titer associated with protec-
tion from infection in GI.1968-challenged subjects) (31), rechal-
lenge studies are needed to evaluate the correlation between anti-
body blockade titer and protection from homotypic virus
infection. Similarly, although five of six uninfected subjects had
preexisting blockade titers to GII.2.1976, we are unable to deter-
mine the impact of antibody-mediated protection from infection
in this study because five of the six uninfected subjects received the
lowest dose of inoculum administered (37). This dosage differ-
ence prevents us from speculating on whether preexisting anti-
bodies offer protection, but it is noteworthy that two out of six of
the uninfected subjects mounted strong CD4 T cell responses to
GII.2.1976 SMV postchallenge, suggesting that even at the lowest
challenge dose, the inoculum was immunostimulatory in some
individuals (37). Here, the same two subjects also had higher day
0 blockade titers and, together with a third uninfected volunteer,
demonstrated more cross-strain blockade activity at day 0 (data
not shown), further supporting previous claims (37) that some
subjects may have been protected from GII.1976 infection by pre-
existing acquired immunity.
How the presence of preexisting antibodies from a lifetime of
NoV exposures impacts the immune response to a current NoV
challenge is unknown. The major capsid protein is a primary tar-
get of NoV antibodies (18, 41). Although this protein is highly
heterogeneous between NoV strains, infection with one NoV can
stimulate an antibody response that blocks other strain VLPs, sug-
gesting that divergent NoV strains share common conserved
blockade epitopes and/or antibody responses are influenced by
original antigenic sin (35). The experiments reported here do not
address which of these mechanisms provides the antibody cross-
reactivity, but they do emphasize an important point for vaccine
design. While challenge with GII.2.1976 SMV does not elicit a
broad cross-genotype blockade response universally, three of six
infected subjects had at least a 4-fold increase in blockade titer to
non-GII.2 VLPs. These data support other findings indicating that
blockade antibodies are activated to not only the challenging NoV
strain but also other NoV strains, a key benefit for a successful
vaccine design against a diverse, evolving pathogen (35, 36, 48).
Further supporting the potential for NoV vaccine design, the
data provided here suggest that a component protective against
GII.2 NoV will not need to be reformulated frequently. Analysis of
antibody blockade of VLPs representing GII.2 strains that have
circulated from 1976 until 2010 suggests that limited evolution
has occurred within the GII.2 genotype, as none of the polyclonal
serum or MAbs lost reactivity to any of the time-ordered GII.2
VLPs. Interestingly, most of the amino acid substitutions that oc-
curred over time resulted in changes that were exposed to the
surface, with the majority of changes from 2008 and 2010 appear-
ing to occur in or around the putative carbohydrate binding sites.
These residue changes were not significant enough to ablate anti-
body binding, but they did moderately impact the blockade po-
tential of antibodies. Sera from GII.2.1976-infected subjects
blocked GII.2.1976 preferentially to GII.2.2008 and -2010, indi-
cating some blockade epitope evolution between the GII.2 strains
over 34 years. Limited epitope evolution is supported by MAb
reactivity, as none of the VLPs lost reactivity to any of the MAb by
EIA or blockade assay. At this time, it is not clear how much
divergence in antibody epitopes is needed to escape from herd
immunity. Studies with GII.4 human NoV, mouse NoV, and
other RNA viruses have demonstrated significant changes in
blockade or neutralization potential with only a single amino acid
change (34, 49–51). It is possible that with an expanded panel of
GII.2 blockade MAbs, we may have been able to more clearly
antigenically differentiate the GII.2 VLPs. The lack of clear GII.2
antigenic phenotypes made it impossible for us to predict and test
potential blockade epitopes as we have done in the past for GII.4
NoVs. Monoclonal antibodies did identify at least one blockade,
conformation-dependent epitope and up to four nonblockade
conformation-dependent epitopes. Another MAb, SMV59 recog-
nizes a pan-NoV, nonblockade, linear epitope. This epitope likely
resides within the shell domain of the major capsid protein (52).
The high degree of cross-reactivity of this antibody makes it po-
tentially useful as a diagnostic reagent. Although we were unable
to map GII.2 epitopes, these antibody studies provide clinically
relevant information about the timing, duration, and cross-reac-
tivity of GII.2.1976 SMV-induced blockade antibody responses.
The assays developed here and the data they provide will be fun-
damental for future GII.2.1976 SMV human challenge studies
slated to begin in the first quarter of 2014 and provide further
support for design of a successful NoV vaccine.
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FIG 7 Anti-GII.2.1976 SMV mouse MAb blockade reactivity with the panel of
GII.2 time-ordered VLPs suggests limited GII.2 antigenic divergence over 34
years. Blockade antibody epitopes shared among GII.2 VLPs were measured by
surrogate neutralization assay. Sigmoidal dose-response curves were fit to the
mean percent control binding (percentage of VLP bound to ligand in the
presence of antibody pretreatment compared to the amount of VLP bound in
the absence of antibody pretreatment), and the EC50 was calculated in g/ml.
Error bars represent 95% confidence intervals. Nonblockade MAbs were as-
signed an EC50 of 40 g/ml for statistical analysis and are denoted by data
markers on the graph above the upper limit of detection (dashed line) for
visual comparison. *, VLP with significantly different blockade titer from that
of GII.2.1976.
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